Preimplantation genetic testing for aneuploidy (PGTA)
Preimplantation genetic testing for aneuploidy (PGTA): 24 chromosome screening for aneuploidy in the preimplantation embryo(blastocyst stage)
Study summary
The GETSET trial is a prospective randomized trial designed to evaluate the clinical outcomes of incorporating preimplantation genetic testing for aneuploidies (PGT-A) in elective single embryo transfer in women between 35 and 40 years of age.
Eligibility
Sex
FEMALE
Min age
35 Years
Max age
40 Years
Healthy volunteers
No
Inclusion Criteria:
* Women undergoing IVF of between 35 and 40 years of age at IVF cycle start
* Utilization of Intracytoplasmic Sperm Injection ICSI (recommended) or ---Traditional IVF
* Utilization of ejaculated or testicular sperm
* Utilization of autologous or donor sperm
* All Controlled Ovarian Hyperstimulation (COH) protocols
Exclusion Criteria:
* Utilization of donor oocytes
* Utilization of gestational carrier
* Recurrent Pregnancy Loss (RPL) defined as ≥ 3 consecutive miscarriages
* Recurrent Implantation Failure (RIF) defined as ≥ 3 more failed embryo transfers
* Preimplantation genetic testing for monogenic/single gene disorders (PGT-M)
* Translocation carriers
Primary outcome measure(s)
Ongoing Pregnancy Rate — Up to 2 years The number of participants who experience an ongoing clinical pregnancy rate after the 1st embryo transfer.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.